Display options
Cite
De-Colle C, Mönnich D, Welz S, et al. SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. Clin Transl Radiat Oncol. 2017;5:28-36doi: 10.1016/j.ctro.2017.06.004.
De-Colle, C., Mönnich, D., Welz, S., Boeke, S., Sipos, B., Fend, F., Mauz, P. S., Tinhofer, I., Budach, V., Jawad, J. A., Stuschke, M., Balermpas, P., Rödel, C., Grosu, A. L., Abdollahi, A., Debus, J., Bayer, C., Belka, C., Pigorsch, S., Combs, S. E., Lohaus, F., Linge, A., Krause, M., Baumann, M., Zips, D., & Menegakis, A. (2017). SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. Clinical and translational radiation oncology, 528-36. https://doi.org/10.1016/j.ctro.2017.06.004
De-Colle, Chiara, et al. "SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy." Clinical and translational radiation oncology vol. 5 (2017): 28-36. doi: https://doi.org/10.1016/j.ctro.2017.06.004
De-Colle C, Mönnich D, Welz S, Boeke S, Sipos B, Fend F, Mauz PS, Tinhofer I, Budach V, Jawad JA, Stuschke M, Balermpas P, Rödel C, Grosu AL, Abdollahi A, Debus J, Bayer C, Belka C, Pigorsch S, Combs SE, Lohaus F, Linge A, Krause M, Baumann M, Zips D, Menegakis A. SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. Clin Transl Radiat Oncol. 2017 Jul 14;5:28-36. doi: 10.1016/j.ctro.2017.06.004. eCollection 2017 Aug. PMID: 29594214; PMCID: PMC5833920.
Copy Download .nbib Format: NLM
Share it on

Clin Transl Radiat Oncol. 2017 Jul 14;5:28-36. doi: 10.1016/j.ctro.2017.06.004. eCollection 2017 Aug.

SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy.

Clinical and translational radiation oncology

Chiara De-Colle, David Mönnich, Stefan Welz, Simon Boeke, Bence Sipos, Falko Fend, Paul-Stefan Mauz, Inge Tinhofer, Volker Budach, Jehad Abu Jawad, Martin Stuschke, Panagiotis Balermpas, Claus Rödel, Anca-Ligia Grosu, Amir Abdollahi, Jürgen Debus, Christine Bayer, Claus Belka, Steffi Pigorsch, Stephanie E Combs, Fabian Lohaus, Annett Linge, Mechthild Krause, Michael Baumann, Daniel Zips, Apostolos Menegakis

Affiliations

  1. Radiation Oncology, Medical Faculty and University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany.
  2. German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Tübingen, Germany.
  3. Department of Pathology, Medical Faculty and University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany.
  4. Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty and University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany.
  5. German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Berlin, Germany.
  6. Department of Radiooncology and Radiotherapy, Charité University Hospital, Berlin, Germany.
  7. German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Essen, Germany.
  8. Department of Radiotherapy, Medical Faculty, University of Duisburg-Essen, Essen, Germany.
  9. German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Frankfurt, Germany.
  10. Department of Radiotherapy and Oncology, Goethe-University Frankfurt, Germany.
  11. German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Freiburg, Germany.
  12. Department of Radiation Oncology, University of Freiburg, Germany.
  13. German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Heidelberg, Germany.
  14. Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Germany.
  15. Heidelberg Ion Therapy Center (HIT), Department of Radiation Oncology, University of Heidelberg Medical School, Germany.
  16. National Center for Tumor Diseases (NCT), University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Germany.
  17. Translational Radiation Oncology, University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Germany.
  18. Clinical Cooperation Unit Radiation Oncology, University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Germany.
  19. German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Munich, Germany.
  20. Department of Radiotherapy and Radiation Oncology, Ludwig-Maximilians-Universität, Munich, Germany.
  21. Department of Radiation Oncology, Technische Universität München, Institute for Innovative Radiation Therapy in Helmholtz-Zentrum München, Germany.
  22. German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK), Dresden, Germany.
  23. Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany.
  24. OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Germany.
  25. National Center for Tumor Diseases (NCT), Dresden, Germany.
  26. Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology - OncoRay, Germany.
  27. German Cancer Research Center (DKFZ), Heidelberg, Germany.

PMID: 29594214 PMCID: PMC5833920 DOI: 10.1016/j.ctro.2017.06.004

Abstract

INTRODUCTION: Outcome after postoperative radiochemotherapy (RT-CT) for patients with advanced head and neck squamous cell carcinomas (HNSCC) remains unsatisfactory, especially among those with HPV negative tumours. Therefore, new biomarkers are needed to further define subgroups for individualised therapeutic approaches. Preclinical and first clinical observations showed that the chemokine receptor CXCR4 and its ligand SDF-1 (CXCL12) play an important role in tumour cell proliferation, survival, cancer progression, metastasis and treatment resistance. However, the data on the prognostic value of SDF-1/CXCR4 expression for HNSCC are conflicting. The aim of our hypothesis-generating study was to retrospectively explore the prognostic potential of SDF-1/CXCR4 in a well-defined cohort of HNSCC patients collected within the multicenter biomarker study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).

MATERIAL AND METHODS: Patients with stage III and IVA HNSCC of the oral cavity, oropharynx and hypopharynx were treated with resection and adjuvant radiotherapy (RT) with ≥60 Gy and concurrent cisplatin-based chemotherapy (CT). Tissue micro-arrays (TMAs) from a total of 221 patients were generated from surgical specimens, 201 evaluated for the SDF-1 and CXCR4 expression by immunofluorescence and correlated with clinico-pathological and outcome data.

RESULTS: In univariate and multivariate analyses intracellular SDF-1 expression was associated with lower loco-regional control (LRC) in the entire patient group as well as in the HPV16 DNA negative subgroup. CXCR4 expression showed a trend for lower LRC in the univariate analysis which was not confirmed in the multivariate analysis. Neither for SDF-1 nor CXCR4 expression associations with distant metastasis free or overall survival were found.

CONCLUSIONS: Our exploratory data support the hypothesis that overexpression of intracellular SDF-1 is an independent negative prognostic biomarker for LRC after postoperative RT-CT in high-risk HNSCC. Prospective validation is warranted and further exploration of SDF-1/CXCR4 as a potential therapeutic target to overcome treatment resistance in HNSCC appears promising.

Keywords: Biomarker; CXCR4; Head and neck cancer; Postoperative radiochemotherapy; Prognostic; SDF-1

References

  1. Int J Cancer. 2015 Mar 1;136(5):E359-86 - PubMed
  2. J Pathol. 2012 Jan;226(2):148-57 - PubMed
  3. Cancer Res. 2013 Mar 15;73(6):1668-75 - PubMed
  4. Int J Oncol. 2013 Dec;43(6):1817-23 - PubMed
  5. Int J Cancer. 2016 Jan 1;138(1):171-81 - PubMed
  6. J Thorac Cardiovasc Surg. 2009 Mar;137(3):615-21 - PubMed
  7. Eur Arch Otorhinolaryngol. 2016 Dec;273(12 ):4525-4533 - PubMed
  8. Mol Cancer Res. 2007 Jul;5(7):685-94 - PubMed
  9. J Clin Invest. 2010 Mar;120(3):694-705 - PubMed
  10. Virchows Arch. 2017 Feb;470(2):185-196 - PubMed
  11. Radiother Oncol. 2014 Dec;113(3):317-23 - PubMed
  12. Front Cell Neurosci. 2014 May 28;8:144 - PubMed
  13. CA Cancer J Clin. 2017 Jan;67(1):7-30 - PubMed
  14. Tumour Biol. 2016 May;37(5):6099-105 - PubMed
  15. Cell Adh Migr. 2009 Oct-Dec;3(4):328-33 - PubMed
  16. PLoS One. 2012;7(2):e31226 - PubMed
  17. Hua Xi Kou Qiang Yi Xue Za Zhi. 2007 Aug;25(4):392-5 - PubMed
  18. J Thorac Oncol. 2011 Jul;6(7):1169-78 - PubMed
  19. Int J Oral Sci. 2009 Sep;1(3):105-18 - PubMed
  20. Clin Cancer Res. 2005 Jul 1;11(13):4658-65 - PubMed
  21. Int J Oncol. 2006 Nov;29(5):1133-8 - PubMed
  22. Oncogene. 2013 Jan 10;32(2):209-21 - PubMed
  23. Eur J Cancer. 2016 Apr;57:78-86 - PubMed
  24. Clin Cancer Res. 2015 Oct 1;21(19):4278-85 - PubMed
  25. Carcinogenesis. 2008 Aug;29(8):1519-27 - PubMed
  26. Oral Oncol. 2011 Nov;47(11):1062-8 - PubMed
  27. Cancer Res. 2007 Aug 1;67(15):7518-24 - PubMed
  28. Nat Rev Cancer. 2011 Jul 22;11(8):573-87 - PubMed
  29. Cancer Res. 2010 Jul 15;70(14):5679-85 - PubMed
  30. N Engl J Med. 2004 May 6;350(19):1937-44 - PubMed
  31. Brain. 2006 Sep;129(Pt 9):2426-35 - PubMed
  32. Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e669-76 - PubMed
  33. Clin Cancer Res. 2005 Apr 15;11(8):2937-46 - PubMed
  34. Int J Radiat Biol. 2014 Aug;90(8):687-99 - PubMed
  35. Oncotarget. 2015 Oct 27;6(33):34494-509 - PubMed
  36. Semin Immunol. 2003 Feb;15(1):49-55 - PubMed
  37. J Oral Pathol Med. 2009 Feb;38(2):214-9 - PubMed
  38. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7 - PubMed
  39. Int J Oncol. 2006 Jan;28(1):61-6 - PubMed
  40. Onco Targets Ther. 2013 Sep 30;6:1347-61 - PubMed
  41. Cancer Lett. 2004 Oct 28;214(2):231-41 - PubMed
  42. Cell. 2015 Sep 24;163(1):160-73 - PubMed
  43. Mol Ther. 2012 Feb;20(2):398-407 - PubMed
  44. Br J Cancer. 2008 May 20;98(10):1682-9 - PubMed
  45. Oral Oncol. 2012 Dec;48(12):1263-71 - PubMed
  46. Strahlenther Onkol. 2016 Jan;192(1):47-54 - PubMed
  47. Clin Cancer Res. 2011 Apr 15;17(8):2074-80 - PubMed
  48. Lab Invest. 2004 Dec;84(12):1538-46 - PubMed
  49. Anticancer Res. 2008 Mar-Apr;28(2B):1355-9 - PubMed
  50. Radiother Oncol. 2011 Oct;101(1):80-5 - PubMed
  51. N Engl J Med. 2004 May 6;350(19):1945-52 - PubMed
  52. Oncol Rep. 2013 Feb;29(2):579-84 - PubMed
  53. Nat Rev Cancer. 2004 Jul;4(7):540-50 - PubMed
  54. Head Neck. 2013 Dec;35(12):1819-28 - PubMed
  55. Int J Colorectal Dis. 2010 Oct;25(10):1185-91 - PubMed
  56. Oncol Rep. 2013 Jun;29(6):2325-31 - PubMed
  57. Mol Cancer Res. 2011 Feb;9(2):161-72 - PubMed
  58. Cancer Microenviron. 2009 Dec;2(1):1-7 - PubMed
  59. Oncotarget. 2015 Mar 10;6(7):5022-40 - PubMed
  60. Oncotarget. 2016 Mar 22;7(12 ):14259-78 - PubMed
  61. Clin Cancer Res. 2016 Jun 1;22(11):2639-49 - PubMed

Publication Types